Kolexia
Gadaud Noemie Hématologie
Gadaud Noemie
Hématologie
Centre Hospitalier de Bigorre
Tarbes, France
46 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie aigüe myéloïde Leucémies Leucémie myéloïde Récidive tumorale locale Hyperpigmentation Toxidermies Infections bactériennes Maladies de la peau Leucémie chronique lymphocytaire à cellules B

Collaborateurs

Voir plus
Recher Christian
Recher Christian
Hôpital Purpan, Toulouse, France
Bertoli Sarah
Bertoli Sarah
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Tavitian Suzanne
Tavitian Suzanne
Oncopole Toulouse, Toulouse, France
Berard Emilie
Berard Emilie
Hôpital Purpan, Toulouse, France

Industries

Voir plus
Abbvie
5 collaboration(s)
Dernière en 2023
Janssen
5 collaboration(s)
Dernière en 2023
Novartis
4 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Cancer medicine   26 février 2024
Levofloxacin to Prevent Bacterial Infection in Patients with Acute Myeloid Leukemia Treated By Azacitidine and Venetoclax: A Study from the Dataml Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Vitamin C and D Supplementation in Acute Myeloid Leukemia.
Blood advances   06 septembre 2023
Improving Patient Selection for Phase I Trials in Hematology: An External Validation of the Gustave Roussy Scoring System at Toulouse University Cancer Institute, Oncopole (IUCT-O)
Annual Meeting Abstracts 2022   15 novembre 2022
"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies.
Hematological oncology   08 mars 2022
Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
Leukemia & lymphoma   04 janvier 2022
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
Nature cancer   11 novembre 2021
Real-World Outcomes of Patients with Refractory or Relapsed -ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.
Cancers   24 juillet 2020
Outcome of Relapsed or Refractory -Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study.
Cancers   25 mars 2020
More than ten percent of relapses occur after five years in AML patients with mutation.
Leukemia & lymphoma   05 février 2020